Methylation of PRDM2, PRDM5 and PRDM16 genes in lung cancer cells

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 5, 2014, Pages 2305-2311

  Tan, Shuang Xiang ^a   Hu, Rui Cheng ^b   Liu, Jing Jing ^b   Tan, Yong Li ^b   Liu, Wen En ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Hunan Province Geriatric Hospital   (China)

Author keywords

Epigenetics; Gene expression; Lung cancer; Methylation; PRDM

Indexed keywords

AZACITIDINE; DECITABINE; DNA BINDING PROTEIN; DNA METHYLTRANSFERASE; ENZYME INHIBITOR; HISTONE LYSINE METHYLTRANSFERASE; MESSENGER RNA; NUCLEAR PROTEIN; PRDM16 PROTEIN, HUMAN; PRDM2 PROTEIN, HUMAN; PRDM5 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DNA METHYLATION; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; PROMOTER REGION; TIME; TUMOR CELL LINE;

AZACITIDINE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LUNG NEOPLASMS; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TIME FACTORS; TRANSCRIPTION FACTORS;

EID: 84902457059     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Chen W, Zheng R, Zhang S, Zou X, Zhao P, He J. Lung cancer incidence and mortality in China, 2009. Thorac Cancer 2013; 4: 102-108.
2. Yang SH, Li SL, Dong ZM, Kan QC. Epigenetic inactivation of Wnt inhibitory factor-1 in human esophageal squamous cell carcinoma. Oncol Res 2012; 20: 123-130.
3. Agarwal A, Polineni R, Hussein Z, Vigoda I, Bhagat TD, Bhattacharyya S, Maitra A, Verma A. Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Int J Clin Exp Pathol 2012; 5: 382-396.
4. Mendoza-Rodriguez M, Arreola H, Valdivia A, Peralta R, Serna H, Villegas V, Romero P, Alvarado-Hernández B, Paniagua L, Marrero-Rodríguez D, Meraz MA, Salcedo M. Cellular retinol binding protein 1 could be a tumor suppressor gene in cervical cancer. Int J Clin Exp Pathol 2013; 6: 1817-1825.
5. Fumasoni I, Meani N, Rambaldi D, Scafetta G, Alcalay M, Ciccarelli FD. Family expansion and gene rearrangements contributed to the functional specialization of PRDM genes in vertebrates. BMC Evol Biol 2007; 7: 471-2148.
6. Watanabe Y, Toyota M, Kondo Y, Suzuki H, Imai T, Ohe-Toyota M, Maruyama R, Nojima M, Sasaki Y, Sekido Y, Hiratsuka H, Shinomura Y, Imai K, Itoh F, Tokino T. PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer. Clin Cancer Res 2007; 13: 4786-4794.
7. Nishikawa N, Toyota M, Suzuki H, Honma T, Fujikane T, Ohmura T, Nishidate T, Ohe-Toyota M, Maruyama R, Sonoda T, Sasaki Y, Urano T, Imai K, Hirata K, Tokino T. Gene amplification and overexpression of PRDM14 in breast cancers. Cancer Res 2007; 7: 9649-9657.
8. Goh L, Murphy SK, Muhkerjee S, Furey TS. Genomic sweeping for hypermethylated genes. Bioinformatics 2007; 23: 281-288.
9. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001; 134: 573-586.
10. Deng Q, Huang S. PRDM5 is silenced in human cancers and has growth suppressive activities. Oncogene 2004; 23: 4903-4910.
11. Watanabe Y, Toyota M, Kondo Y, Suzuki H. PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer. Clin Cancer Res 2007; 13: 4786-4794.
12. Duhoux FP, Ameye G, Montano-Almendras CP, Bahloula K, Mozziconacci MJ, Laibe S, Wlodarska I, Michaux L, Talmant P, Richebourg S, Lippert E, Speleman F, Herens C, Struski S, Raynaud S, Auger N, Nadal N, Rack K, Mugneret F, Tigaud I, Lafage M, Taviaux S, Roche-Lestienne C, Latinne D, Libouton JM, Demoulin JB, Poirel HA; Groupe Francophone de Cytogénétique Hématologique (GFCH); Belgian Cytogenetic Group for Haematology and Oncology (BCG-HO). PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies. Br J Haematol 2012; 156: 76-88.
13. Gronbaek K, Hother C, Jones PA. Epigenetic changes in cancer. APMIS 2007; 115: 1039-1159.
14. Khandige S, Shanbhogue VV, Chakrabarty S, Kapettu S. Methylation markers: a potential force driving cancer diagnostics forward. Oncol Res 2011; 19: 105-110.
15. Shu XS, Geng H, Li L, Ying J, Ma C, Wang Y, Poon FF, Wang X, Ying Y, Yeo W, Srivastava G, Tsao SW, Yu J, Sung JJ, Huang S, Chan AT, Tao Q. The epigenetic modifier PRDM5 functions as a tumor suppressor through modulating WNT/β-catenin signaling and is frequently silenced in multiple tumors. PLoS One 2011; 6: e27346.